Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SMT19969 - a phase I, randomised, partially-blind, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of single and multiple oral escalating doses in male healthy subjects

Next Previous
X
Search
Trial Profile

SMT19969 - a phase I, randomised, partially-blind, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of single and multiple oral escalating doses in male healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ridinilazole (Primary)
  • Indications Clostridium difficile infections
  • Focus Adverse reactions; First in man
  • Sponsors Summit plc

    • Most Recent Events

    • 07 Oct 2018 Results assessing pharmacokinetics and safety of Ridinilazole from phase 1 and 2 trial presented at the IDWeek 2018
    • 13 Sep 2013 Results assessing effects of multiple doses of SMT 19969 (groups G and H) on gut flora presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 11 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top